Tag: drug approval
-
AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
The FDA approved AbbVie’s Juvmo (tavapadon), a once-daily oral D1/D5 dopamine receptor partial agonist, for adults with Parkinson’s disease. Phase 3 TEMPO data support its efficacy, while pricing, coverage and real-world tolerability remain key commercial questions.